| 货号 | AF1587-SP |
| 别名 | interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2 | 全称 | Interleukin 28A |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunocytochemistry(5-15 µg/mL) |
| 目标/特异性 | Detects human IL‑28A/IFN‑ lambda 2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 60% cross-reactivity with human IL‑28B/IFN‑ lambda 3 is observed. In direct ELISAs, approximately 30% cross-reactivity with recombinant human IL-29 and less than 5% cross‑reactivity with recombinant mouse IL‑28 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunocytochemistry: 5-15 µg/mL Neutralization: Measured by its ability to neutralize IL‑28A/IFN‑ lambda 2 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND50) is typically 0.3-1.5 µg/mL in the presence of 0.1 µg/mL Recombinant Human IL‑28A/IFN‑ lambda 2. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 282616 (Human) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-kappaB-mediated MMP-9 expression inducing the MAPK pathway. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human IL-28A/IFN-lambda 2 Val26-Val200 Accession # Q8IZJ0 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% aa sequence identity) and type I IFN family (15-19% aa sequence identity) (1-3). The genes encoding these three cytokines are localized to chromosome 19 and each is composed of multiple exons. The exon organization of these genes is also found in the IL-10 family genes but is distinct from the type I IFNs, which are encoded within a single exon, The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including anti-viral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor beta (IL-10 R beta ) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a putative 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
IL‑28A/IFN‑ lambda 2 Inhibition of EMCV‑induced Cytopathy and Neutralization by Human IL‑28A/IFN‑ lambda 2 Antibody. Recombinant Human IL‑28A/ IFN‑ lambda 2 (Catalog # 1587‑IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL‑28A/IFN‑ lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND50 is typically 0.3-1.5 µg/mL. | |
IL‑28A/IFN‑ lambda 2 in Human PBMCs. IL‑28A/IFN‑ lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips. |
